An enzyme, called S-1117, can disarm self-reactive immunoglobulin G (IgG) antibodies targeting the acetylcholine receptor (AChR) that drive most cases…
Michela Luciano, PhD
Science Writer
Michela Luciano, PhD, is a science writer and molecular biologist with academic and research background in oncology and immunology. She holds a PhD from the University of Salzburg, where she was part of the Immunity in Cancer and Allergy doctoral program. Her work has contributed to multiple peer-reviewed publications in international journals, with a focus on inflammation, leukemogenesis, and molecular pathways involved in acute myeloid leukemia. With a passion for clear and impactful scientific communication, she transitioned into science writing in 2022, taking on her first role as a science writer. In 2025, she joined Bionews, where she continues to translate complex biomedical research into accessible content. She is a member of the European Medical Writers Association and continually pursues opportunities to grow and enhance her expertise in science communication.
Education
- PhD in Biosciences and Medical Biology, University of Salzburg, Austria (2017–2022), Doctoral Program: Immunity in Cancer and Allergy (ICA)
- MSc in Medical Biotechnology, University of L’Aquila, Italy (2011–2014)
- BSc in Biotechnology, University of L’Aquila, Italy (2006–2011)
Certifications
- 2023 – Editing and Proofreading Essentials, EMWA
Professional Organizations and Affiliations
- European Medical Writers Association (EMWA) – Member since 2023
Published Works
- Sieberer H, Luciano M, et al. Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML. Cell Communication and Signaling. 2025;23(1):53. DOI:10.1186/s12964-025-02046-w. PMID:38864235.
- Luciano M, et al. Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis. Cell Communication and Signaling. 2024;22(1):424. DOI:10.1186/s12964-024-01777-6. PMID:39223663.
- Blöchl C, Holzner C, Luciano M, et al. Proteolytic profiling of Streptococcal Pyrogenic Exotoxin B (SpeB) by complementary HPLC-MS approaches. International Journal of Molecular Sciences. 2022;23(1):412. DOI:10.3390/ijms23010412. PMID:35055459.
- Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Frontiers in Immunology. 2022;13:1000996. DOI:10.3389/fimmu.2022.1000996. PMC9554002. PMID:36248849.
- Urwanisch L, Luciano M, Horejs-Hoeck J. The NLRP3 inflammasome and its role in the pathogenicity of leukemia. International Journal of Molecular Sciences. 2021;22(3):1271. DOI:10.3390/ijms22031271. PMC7865748. PMID:33525345.
- Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators. Cytokine & Growth Factor Reviews. 2018;43:8–15. DOI:10.1016/j.cytogfr.2018.08.004. PMID:30181021.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
In Japan, myasthenia gravis (MG) was associated with an older age at onset and better clinical outcomes in 2018…
Telitacicept, a B-cell-targeting therapy for myasthenia gravis (MG), has been granted orphan drug status in the European Union,…
A six-week program that combines inspiratory muscle training (IMT) and aerobic exercise may improve respiratory function in adults with…